{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000022","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.432085+00:00","generated_at":"2026-06-02T02:08:48.254336+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Stockholders approve 2.7M share increase under 2018 Equity Plan, re-elect all directors at annual meeting","bullets":["All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.","2018 Equity Plan amended to add 2.7M authorized shares; vote 36.4M for, 22.1M against.","Advisory say-on-pay passed with 55.8M for, 2.9M against, 42k abstain.","Ernst & Young ratified as FY2024 auditor with 60.5M for, 2.2M against, 52k abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000022","json":"https://secwatch.observer/filing/0001438533-24-000022.json","markdown":"https://secwatch.observer/filing/0001438533-24-000022.md","text":"https://secwatch.observer/filing/0001438533-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/tvtx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:08:48.254336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c5dcd636b2bcc75552434e749aaa6ef273d5e4a","claim":"Travere Therapeutics, Inc. shareholders approved Approval of the Company’s 2018 Equity Incentive Plan, as amended at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"5a16cd2e67e356e17d825b1c50de92c6a171764f","claim":"Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2025 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"7625da6e7f184b920f1d3dd636a0350bf5b4e376","claim":"Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"e5fee682e474d8d79902c0fecbeb59ee75eabf2b","claim":"Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}